Multiple recent regulatory decisions and clinical trial updates are shaping biopharma pipelines. The FDA approved Leo Pharma’s Anzupgo, the first treatment for chronic hand eczema, expanding therapeutic options. AstraZeneca reported positive phase III results for gefurulimab in myasthenia gravis, positioning the therapy for potential regulatory submission. Conversely, FDA delayed decisions on GSK’s Blenrep, reflecting ongoing safety assessments. These updates reflect dynamic shifts in product development, with implications for market access and patient care.